General Oncology, Inc., a clinical-stage biopharmaceutical company creating medicines for metastatic cancers, announced the appointment of Abid Ansari as Chief Financial Officer (CFO). 

Abid brings over 20 years of experience in the biotechnology sector, including eight years as a CFO. He has expertise in financial strategy and corporate development for public and private life science companies. 

He has led multiple successful capital-raising initiatives, including initial public offerings (IPOs) and large-scale private funding rounds, and has extensive experience with business development transactions, including merger and acquisition agreements and in-licensing/out-licensing deals.

Jeff Glazier, CEO of General Oncology, said, “With deep expertise in strategic financial leadership, capital raising, and business development, Abid is exceptionally well-suited to help drive our financial strategy as we advance our pipeline. His leadership will be instrumental in securing a strong foundation to support our next phase of growth, including our upcoming clinical readout and a potentially pivotal trial, and ultimately delivering on our mission to bring innovative therapies to cancer patients in need.”